Immunocore Holdings plc (IMCR)
NASDAQ: IMCR · Real-Time Price · USD
29.09
-0.49 (-1.66%)
Mar 31, 2025, 1:13 PM EDT - Market open
Immunocore Holdings Revenue
In the year 2024, Immunocore Holdings had annual revenue of $310.20M with 24.37% growth. Immunocore Holdings had revenue of $84.05M in the quarter ending December 31, 2024, with 19.80% growth.
Revenue (ttm)
$310.20M
Revenue Growth
+24.37%
P/S Ratio
4.77
Revenue / Employee
$629,213
Employees
493
Market Cap
1.46B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 310.20M | 60.77M | 24.37% |
Dec 31, 2023 | 249.43M | 75.07M | 43.05% |
Dec 31, 2022 | 174.36M | 137.88M | 377.91% |
Dec 31, 2021 | 36.48M | 6.37M | 21.15% |
Dec 31, 2020 | 30.11M | 4.45M | 17.32% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
IMCR News
- 20 days ago - Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 - GlobeNewsWire
- 4 weeks ago - Immunocore to present at upcoming investor conferences - GlobeNewsWire
- 4 weeks ago - Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even Point - Seeking Alpha
- 4 weeks ago - Immunocore Holdings plc (IMCR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Immunocore reports fourth quarter and full year 2024 financial results and provides a business update - GlobeNewsWire
- 5 weeks ago - Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025 - GlobeNewsWire
- 2 months ago - Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire